Literature DB >> 14595658

On symptomatic heterozygous alpha-sarcoglycan gene mutation carriers.

Dirk Fischer1, Stefania Aurino, Vincenzo Nigro, Rolf Schröder.   

Abstract

Mutations in the human alpha-sarcoglycan gene on chromosome 17q21.2 have been shown to cause a severe childhood autosomal recessive muscular dystrophy, a less severe limb girdle muscular dystrophy, exercise intolerance, or asymptomatic hyperCKemia. Here, we describe the clinical findings in a German family harboring a 371 T > C (Ile124Thr) missense mutation in the alpha-sarcoglycan gene. Whereas our index patient, an 11-year-old girl homozygous for this mutation, presented with a severe Duchenne-like phenotype, 7 out of 12 heterozygous mutation carriers from three generations showed mild to moderate scapular winging. In analogy to symptomatic female dystrophinopathy carriers, our results suggest that heterozygous alpha-sarcoglycan gene mutation carriers can be symptomatic with selective muscle weakness. This finding may be attributed to an additional negative variation in a yet unknown modifier gene essential to the function of the sarcoglycan complex in shoulder girdle muscles.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14595658     DOI: 10.1002/ana.10738

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  2 in total

1.  Molecular diagnosis of hereditary inclusion body myopathy by linkage analysis and identification of a novel splice site mutation in GNE.

Authors:  Steven E Boyden; Anna R Duncan; Elicia A Estrella; Hart G W Lidov; Lane J Mahoney; Jonathan S Katz; Louis M Kunkel; Peter B Kang
Journal:  BMC Med Genet       Date:  2011-06-28       Impact factor: 2.103

2.  Diagnostic value of muscle MRI in differentiating LGMD2I from other LGMDs.

Authors:  Dirk Fischer; Maggie C Walter; Kristina Kesper; Jens A Petersen; Stefania Aurino; Vincenzo Nigro; Christian Kubisch; Thomas Meindl; Hanns Lochmüller; Kai Wilhelm; Horst Urbach; Rolf Schröder
Journal:  J Neurol       Date:  2005-02-23       Impact factor: 4.849

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.